Literature DB >> 21704399

miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer.

Laurent Quero1, Ludwig Dubois, Natasja G Lieuwes, Christophe Hennequin, Philippe Lambin.   

Abstract

INTRODUCTION: Radiotherapy in combination with medical castration is the standard treatment for high-risk prostate cancer. Some relapses may be explained by the presence of radioresistant clones arising from hypoxic microenvironment. Since microRNAs (miR) are increased upon hypoxia, the aim of this study was to see whether miR-210 is a potential marker for hypoxia and/or a therapeutic target in prostate cancer.
METHODS: Human LNCaP, DU145 or PC3 prostate cancer cells were exposed to normoxia or hypoxia for several hours. Gene expression of miR-210, miR-373 and several hypoxia markers were analyzed by Taqman and SYBR green qRT-PCR, respectively. Clonogenic survival after LNA miR-210 inhibitor (78 nM) and concomitant irradiation were evaluated.
RESULTS: During anoxia, CAIX and VEGF expressions were dramatically increased. miR-210 expression increased during anoxia exposure, while basal miR-373 expression was low and remained stable upon anoxia. LNA miR-210 inhibitor decreased anoxic miR-210 expression by 90% and clonogenic survival under anoxia (p=0.01). However, no enhanced effect was observed when miR-210 inhibitor was combined with irradiation.
CONCLUSION: miR-210 could be an interesting marker of chronic hypoxia irrespective of the androgen dependency and should, therefore, be tested as a prognostic marker in high risk prostate cancer patients. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704399     DOI: 10.1016/j.radonc.2011.05.063

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  21 in total

1.  Huoxue Anxin Recipe () promotes myocardium angiogenesis of acute myocardial infarction rats by up-regulating miR-210 and vascular endothelial growth factor.

Authors:  Jie Wang; Yun Zhang; Yong-Mei Liu; Li-Li Guo; Ping Wu; Yu Dong; Guang-Jun Wu
Journal:  Chin J Integr Med       Date:  2016-07-09       Impact factor: 1.978

Review 2.  Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Yiwei Li; Aamir Ahmad; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

3.  Hypoxia-inducible factor 1-α induces miR-210 in normoxic differentiating myoblasts.

Authors:  Lucia Cicchillitti; Valeria Di Stefano; Eleonora Isaia; Luca Crimaldi; Pasquale Fasanaro; Valeria Ambrosino; Annalisa Antonini; Maurizio C Capogrossi; Carlo Gaetano; Giulia Piaggio; Fabio Martelli
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

Review 4.  Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences.

Authors:  C Bayer; P Vaupel
Journal:  Strahlenther Onkol       Date:  2012-03-29       Impact factor: 3.621

Review 5.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

6.  Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer.

Authors:  A Singer; Y Deuse; U Koch; T Hölscher; D Pfitzmann; C Jakob; S Hehlgans; G B Baretton; A Rentsch; M Baumann; M H Muders; M Krause
Journal:  Strahlenther Onkol       Date:  2012-11-07       Impact factor: 3.621

7.  Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia.

Authors:  Germana Zaccagnini; Biagina Maimone; Valeria Di Stefano; Pasquale Fasanaro; Simona Greco; Alessandra Perfetti; Maurizio C Capogrossi; Carlo Gaetano; Fabio Martelli
Journal:  Antioxid Redox Signal       Date:  2013-10-16       Impact factor: 8.401

Review 8.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

9.  Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.

Authors:  Becky A S Bibby; Niluja Thiruthaneeswaran; Lingjian Yang; Ronnie R Pereira; Elisabet More; Darragh G McArt; Paul O'Reilly; Robert G Bristow; Kaye J Williams; Ananya Choudhury; Catharine M L West
Journal:  BMC Urol       Date:  2021-07-01       Impact factor: 2.264

10.  Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.

Authors:  Bin Bao; Aamir Ahmad; Dejuan Kong; Shadan Ali; Asfar S Azmi; Yiwei Li; Sanjeev Banerjee; Subhash Padhye; Fazlul H Sarkar
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.